Add on topical steroids to Dupilimab monotherapy fail to further improve outcomes in Atopic dermatitis Jacinthlyn Sylvia15 March 2023 2:45 AM ISTAddition of topical corticosteroids to Dupilimab does not further improve the outcomes in patients with moderate to severe Atopic Dermatitis, finds a...
Dupilumab improves urticaria activity and QoL in patients with chronic spontaneous urticaria Medha Baranwal13 March 2023 8:00 PM ISTUSA: A recent study has found that patients with chronic spontaneous urticaria treated with dupilumab experienced a significant improvement in quality...
Sanofi Dupixent application for treatment of chronic spontaneous urticaria in adults, adolescents accepted for USFDA review Ruchika Sharma7 March 2023 3:30 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Dupilumab rapidly improves treatment outcomes in erythrodermic atopic dermatitis Aditi14 Feb 2023 8:00 PM ISTIllinois: An original investigation published in JAMA Dermatology has concluded that Dupilumab improves signs and symptoms of Atopic dermatitis (AD)...
Dupilumab therapy against Atopic dermatitis associated with conjunctivitis Jacinthlyn Sylvia22 Jan 2023 8:00 PM ISTDupilumab had an 86% two-year medication survival rate, however it was ineffective for treating atopic dermatitis (AD) in the head and neck, and 25%...
Dupilumab improves histologic outcomes of eosinophilic esophagitis: NEJM Jacinthlyn Sylvia28 Dec 2022 9:45 AM ISTA new study published in The New England Journal of Medicine suggests that subcutaneous dupilumab given weekly to individuals with eosinophilic...
Dupilumab effective against moderate-to-severe AD across all anatomic regions Dr. Shravani Dali23 Dec 2022 8:00 PM ISTIn adult patients with moderate-to-severe atopic dermatitis, treatment with dupilumab resulted in rapid and sustained improvement in the signs of...
Sanofi gets EMA panel recommendation for Dupixent to treat eosinophilic esophagitis Ruchika Sharma19 Dec 2022 10:30 AM ISTEoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.
Sanofi Dupixent gets European Commission nod for Prurigo Nodularis Ruchika Sharma18 Dec 2022 5:30 PM ISTParis: Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the European Commission (EC) has expanded the marketing authorization for...
Sanofi Dupixent recommended for EU approval by CHMP for prurigo nodularis treatment Ruchika Sharma13 Nov 2022 4:30 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not...
Serum Dupilumab levels fail to reveal treatment response in Atopic Dermatitis at 16 weeks Dr.Niharika Harsha B3 Nov 2022 8:00 PM ISTA new clinical study found that serum dupilumab levels do not affect treatment response and adverse effects during the first year of treatment at 16...
Dupilumab reduces exacerbations and improves FEV1 in uncontrolled, moderate-to-severe asthma Dr.Niharika Harsha B24 Oct 2022 8:00 PM ISTA recent study found that in patients having uncontrolled, moderate-to-severe asthma Dupilumab showed sustained, long-term reduction in exacerbations...
